Literature DB >> 26118501

The downregulation of BAP1 expression by BCR-ABL reduces the stability of BRCA1 in chronic myeloid leukemia.

Fatima Dkhissi1, Djamel Aggoune2, Julien Pontis3, Nathalie Sorel4, Nathalie Piccirilli4, Amélie LeCorf2, François Guilhot5, Jean-Claude Chomel4, Slimane Ait-Si-Ali3, Ali G Turhan6.   

Abstract

BCR-ABL induces an intrinsic genetic instability in chronic myeloid leukemia (CML). The protein breast cancer 1, early onset (BRCA1)-associated protein 1 (BAP1) is a deubiquitinase interacting with the DNA repair regulator BRCA1 and is frequently inactivated in many cancers. Here, we report that BAP1 mRNA and protein levels are downregulated in a BCR-ABL1-expressing hematopoietic cell line (UT-7/11). A decrease of BAP1 transcripts is also observed in newly diagnosed CML patients. Moreover, BAP1 protein levels are low or undetectable in CD34(+) cells from CML patients at diagnosis as compared with CD34(+) cells from normal donors. In addition, BRCA1 protein level is reduced in BCR-ABL1-expressing UT-7/11 cells. Finally, the enforced expression of BAP1 is associated with BRCA1 protein deubiquitination and restoration. These results demonstrate BAP1 as a major link with the BCR-ABL-induced downregulation of BRCA1 in CML.
Copyright © 2015 ISEH - International Society for Experimental Hematology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26118501     DOI: 10.1016/j.exphem.2015.04.013

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  6 in total

1.  Non-NAD-like PARP1 inhibitor enhanced synthetic lethal effect of NAD-like PARP inhibitors against BRCA1-deficient leukemia.

Authors:  Margaret Nieborowska-Skorska; Silvia Maifrede; Min Ye; Monika Toma; Elizabeth Hewlett; John Gordon; Bac Viet Le; Tomasz Sliwinski; Huaqing Zhao; Katarzyna Piwocka; Peter Valent; Alexei V Tulin; Wayne Childers; Tomasz Skorski
Journal:  Leuk Lymphoma       Date:  2018-10-02

Review 2.  Role of DNA Damage Response in Suppressing Malignant Progression of Chronic Myeloid Leukemia and Polycythemia Vera: Impact of Different Oncogenes.

Authors:  Jan Stetka; Jan Gursky; Julie Liñan Velasquez; Renata Mojzikova; Pavla Vyhlidalova; Lucia Vrablova; Jiri Bartek; Vladimir Divoky
Journal:  Cancers (Basel)       Date:  2020-04-07       Impact factor: 6.639

Review 3.  Mechanisms of Disease Progression and Resistance to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: An Update.

Authors:  Luana Bavaro; Margherita Martelli; Michele Cavo; Simona Soverini
Journal:  Int J Mol Sci       Date:  2019-12-05       Impact factor: 5.923

Review 4.  Ubiquitin Carboxyl-Terminal Hydrolases and Human Malignancies: The Novel Prognostic and Therapeutic Implications for Head and Neck Cancer.

Authors:  Chao Rong; Ran Zhou; Shan Wan; Dan Su; Shou-Li Wang; Jochen Hess
Journal:  Front Oncol       Date:  2021-01-29       Impact factor: 6.244

Review 5.  Genetic Biomarkers in Chronic Myeloid Leukemia: What Have We Learned So Far?

Authors:  Bilal Abdulmawjood; Beatriz Costa; Catarina Roma-Rodrigues; Pedro V Baptista; Alexandra R Fernandes
Journal:  Int J Mol Sci       Date:  2021-11-19       Impact factor: 5.923

6.  Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells.

Authors:  Katherine Sullivan-Reed; Elisabeth Bolton-Gillespie; Yashodhara Dasgupta; Samantha Langer; Micheal Siciliano; Margaret Nieborowska-Skorska; Kritika Hanamshet; Elizaveta A Belyaeva; Andrea J Bernhardy; Jaewong Lee; Morgan Moore; Huaqing Zhao; Peter Valent; Ksenia Matlawska-Wasowska; Markus Müschen; Smita Bhatia; Ravi Bhatia; Neil Johnson; Mariusz A Wasik; Alexander V Mazin; Tomasz Skorski
Journal:  Cell Rep       Date:  2018-06-12       Impact factor: 9.423

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.